MarketMindUS Markets Closed
AI-assisted · Not financial adviceNot adviceAI-assisted · Not financial advice.
+5 older changes
Retail caution on Eli Lilly's options trading aligns with news of expansion in China. Investors should manage risks carefully.
Eli Lilly Expands Oncology Reach in China
Target: $1315 avg (+26% upside)
33 Buy · 9 Hold · 3 Sell
Based on curated news sources (not retail comments)
Over the last 7 days: Eli Lilly is poised for growth with new affordable drug access and strong revenue guidance, although advertising concerns may impact uptake.
Options positioning: Bearish — More betting on downside (2.7× more put than call volume today). Unusual bets on $1150 downside — 4× normal activity. analysts: 33 buy vs 3 sell.